1. Medtech Insight
  2. >>Geography

Medtechs Dig Deep For UK System Positives But Take Issue With MHRA Fees Hike

Delayed GB Regulatory System And NHS Net Zero Roadmap Making Life Tricky

 
• By Ashley Yeo

A new UK medtech survey sets out industry’s market access and regulatory concerns and makes clear where system users see the need for improvement. There are some grounds for optimism, but the MHRA’s planned rise in regulatory fees could undo some of the good work.

NHS
33% of medtechs will find net zero compliance tough (Shutterstock)

The UK medtech industry‘s Pulse of the Sector 2024 survey, capturing members‘ concerns and hopes for the year ahead, has just been published. Its release was signaled at the Association of British HealthTech Industries’ (ABHI) annual conference in early October.

The joint ABHI/CPI survey and report applauds the new UK government’s focus on innovation and its acknowledgement of the role healthtech can play in growing the economy. But all the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.